Virogen Inc. (VRNI), a holding company with specialties

New Post Public Reply Private Reply Replies (2) Message Board
tommyboyboy Lets Roll #5302

[b]Virogen Inc. (VRNI)[/b], a holding company with specialties in data security and encryption technology, today announced the launch of its newest business unit, "The Cannabis Connection", which is intended to operate medicinal marijuana dispensaries in states that have legalized such operations, including California.


With an estimated current annual value of approximately $120 billion (legal and illegal) and expected continued easing of marijuana laws nationwide, the marijuana market appears to be headed for a period of dramatic growth.  In California, The Cannabis Connection's home state, which represents approximately 10% of the overall U.S. market, 95%, or approximately $11 billion, of marijuana sales are made legally through medicinal marijuana dispensaries. The company's management has equated the current state of the legal marijuana industry to the post-prohibition U.S. alcohol industry, in terms of the massive consumer market, volume of consumption, market fragmentation and opportunity for profit.


It is the fragmented nature of the legal marijuana market that provides the greatest source of optimism for the company's management. This highly fragmented market is dominated by independent operators, many of whom were "dealers" prior to the legalization of marijuana, who invested minimal capital and operate their marijuana outlets in areas where overhead is low. It is the market fragmentation coupled with the relative lack of sophistication of existing operators that provide the company with its opportunity to consolidate existing outlets and operate a chain of dispensaries, all within an extremely short timeframe.

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Top 5 Most Recently Viewed Articles

USDA Under Scrutiny as ASPCA Reports on Puppy Mill Violations

Updated Category News Views 322

ASPCA's Shocking Report on Puppy Mill Violations In a recent analysis by the ASPCA, alarming statistics have surfaced regarding animal welfare violations at USDA-licensed commercial dog breeding facilities. The findings reveal that in a given year, substantial breaches of care standards were documented, yet no actions were taken to ensure the safety of the animals....

Continue Reading
PowerReviews Unveils Partner Program to Amplify UGC Value

Updated Category News Views 1653

PowerReviews Launches Comprehensive Partner Program PowerReviews, a reputable name backed by 1WorldSync, has initiated an exciting Partner Program aimed at revolutionizing the way user-generated content (UGC) is leveraged. This initiative is designed to not only boost productivity but also facilitate enhanced revenue opportunities for partners who promote its advanced...

Continue Reading
Turnspire Capital Partners Expands Portfolio with GHP Group

Updated Category News Views 81

Turnspire Capital Partners pulled the trigger on acquiring GHP Group back in 2024, a move that sent shockwaves through the consumer product landscape. This was no random buy; GHP's got its fingers in the pie of outdoor living products—think patio heaters and grills—all under reputable brands like Dyna-Glo and Pleasant Hearth. GHP Group: A Heavyweight Player in Outdoor...

Continue Reading
MPI Corporation Launches Groundbreaking 250 GHz Probe System

Updated Category News Views 187

Enhancing Precision in Semiconductor Testing In the fast-evolving world of semiconductor technology, precision and performance are critical. MPI Corporation has once again demonstrated its innovative spirit by unveiling a revolutionary 250 GHz broadband test solution. This state-of-the-art system combines the power of the TITAN™ Probes and MPI's extensive expertise in...

Continue Reading
Passage Bio's Gene Therapy Strategy: Hope for Dementia Treatments

Updated Category News Views 76

Promising Advances in Gene Therapy Recently, Passage Bio, Inc. (NASDAQ: PASG), a pioneering company in genetic medicine, showcased groundbreaking preclinical and interim clinical results for its gene therapy product, PBFT02. This was presented at a major congress focused on gene and cell therapy. Designed specifically to target frontotemporal dementia associated with GRN...

Continue Reading